Overview

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

Status:
RECRUITING
Trial end date:
2026-05-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of VX-993 in participants with pain associated with Diabetic Peripheral Neuropathy (DPN)
Phase:
PHASE2
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Treatments:
Pregabalin